ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3121-Richmond-Epworth-Freemasons-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT06413498
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma (
iMMagine-3
)
Bortezomib
Carfilzomib
Cyclophosphamide
Daratumumab
Dexamethasone
Fludarabine
Pomalidomide
alkylating agent
anti-CD38 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06392477
Haem
Phase 1
Recruiting
A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (
DR-0201-ONC-001
)
unknown drug class,bispecific antibody
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06215118
Haem
Phase 1
Recruiting
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (
C1071030
)
CELMoD agent
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05499013
Haem
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera (
SLN
)
siRNA therapy,TMPRSS6-targeting
Polycythemia vera
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5037 - Glandore - Ashford Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05475925
Haem
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (
DR-01-ONC-001
)
anti-CD94 monoclonal antibody
Blastic plasmacytoid dendritic cell neoplasm
Gamma-delta T-cell lymphoma
Leukaemia
T-cell lymphoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05466799
Advanced
Phase 2
Recruiting
An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma. (
TRIPP-FFX
)
brachytherapy
Pancreatic cancer
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05445778
Curative
Phase 3
Recruiting
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (
GLORIOSA
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Gold Coast University Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05317416
Haem
Phase 3
Recruiting
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION (
MagnetisMM-7
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4217 - Benowa - Pindara Private Hospital
NCT05259839
Haem
Phase 1
Recruiting
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma (
M22-947
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04789096
Advanced
Phase 2
Recruiting
A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients with Pre-treated Advanced HER2-positive Breast Cancer (
TUGETHER
)
ERBB2 inhibitor,third generation
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Breast cancer
HER2-positive breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT04735575
Haem
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma (
EMB06X101
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
WA
6009 - Nedlands - One Clinical Research
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT04637763
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (
CB10A
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04576156
Haem
Phase 3
Recruiting
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor (
MYF3001
)
telomerase inhibitor
Myelofibrosis
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04516447
Advanced
Phase 1
Recruiting
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer (
ZN-c3-002
)
WEE1 inhibitor
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT03537482
Advanced
Phase 1
Recruiting
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies (
APG2575-001
)
BCL2 inhibitor
Haematological malignancy
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
ACTRN12621001172897
Advanced
Phase 1
Recruiting
A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B). (
ACT001-AU-001
)
NFKB inhibitor
Glioblastoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12621000273886
Curative
Phase 2
Recruiting
The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer -
ADELE
: a randomised phase 2 trial
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06425991
Haem
Phase 1
Active not recruiting
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma (
MajesTEC-10
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05839626
Haem
Phase 1 / Phase 2
Active not recruiting
First-in-human, Open-label Phase 1/2 Study to Investigate Safety and Efficacy of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (
TCD17710
)
BCMA-targeting antibody-based NK cell engager
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT05669989
Haem
Phase 2
Active not recruiting
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05405166
Haem
Phase 3
Active not recruiting
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (
IRAKLIA
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05355298
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients (
AMP945-PC-201
)
FAK inhibitor
antimetabolite
taxane
Pancreatic adenocarcinoma
Pancreatic cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05329545
Advanced
Phase 3
Terminated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (
UP-NEXT
)
anti-NaPi2b antibody-drug conjugate
placebo
Fallopian tube cancer
High-grade serous ovarian cancer
Primary peritoneal serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT05308654
Haem
Phase 1
Active not recruiting
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma (
M21-406
)
BCL2 inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NCT05288166
Advanced
Phase 3
Active not recruiting
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer (
CYCLONE-3
)
CDK4/6 inhibitor
CYP17A1 inhibitor
glucocorticoid
placebo
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
SA
5037 - Glandore - Ashford Cancer Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
ACTRN12621001347853
Advanced
Phase 2
*recruitment paused
A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma (
SPEAR
)
SLC7A11 inhibitor
Pancreatic cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (19)
Active not recruiting (7)
Terminated (1)
*recruitment paused (1)
Recruitment Country and State
VIC (28)
NSW (20)
QLD (14)
SA (13)
WA (12)
TAS (4)
NZ (3)
ACT (1)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (6)
Phase 2 (5)
Phase 3 (8)
Trial Type
Haem (16)
Advanced (9)
Curative (3)
Cancer Therapy Class
cereblon
29%
CD38
21%
BCMA
18%
PD-1
14%
PD-1/PD-L1
14%
proteasome
7%
CDK4
7%
CDK6
7%
VEGF
7%
BCL2
7%
ER
4%
oestrogen axis
4%
TMPRSS6
4%
CD94
4%
FR-alpha
4%
ERBB2
4%
CD47
4%
ROCK2
4%
TGF-beta
4%
CD19
4%
telomerase
4%
WEE1
4%
NFKB
4%
FAK
4%
NaPi2b
4%
CYP17A1
4%
androgen axis
4%
SLC7A11
4%
Facility
3121 - Richmond - Epworth Freemasons Hospital (28)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
2500 - Wollongong - Wollongong Hospital (7)
3168 - Clayton - Monash Medical Centre (7)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
2031 - Randwick - Prince of Wales Hospital (4)
2170 - Liverpool - Liverpool Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (3)
3004 - Melbourne, Southbank - Alfred Health (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
5042 - Bedford Park - Flinders Medical Centre (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
3002 - East Melbourne - Epworth Freemasons (2)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4217 - Benowa - Pindara Private Hospital (2)
5037 - Glandore - Ashford Cancer Centre (2)
4215 - Southport - Gold Coast University Hospital (2)
3066 - Epping - Northern Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2109 - North Ryde - Macquarie University Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
7000 - Hobart - ICON Cancer Care Hobart (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
7000 - Hobart - Royal Hobart Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2217 - Kogarah - St George Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
6009 - Nedlands - One Clinical Research (1)
6000 - Perth - Royal Perth Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4215 - Southport - Tasman Oncology (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Solid tumour
Gynaecological cancer
Lymphoma
Non-Hodgkin's lymphoma
Gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
Breast cancer
Myeloproliferative neoplasm
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary peritoneal serous carcinoma
Polycythemia vera
Blastic plasmacytoid dendritic cell neoplasm
Gamma-delta T-cell lymphoma
Leukaemia
T-cell lymphoma
Breast adenocarcinoma
HER2-positive breast cancer
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Myelofibrosis
Primary fallopian tube serous carcinoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Endometrial cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Male genital cancers
Prostate cancer
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy